Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Halozyme Therapeutics entered into a global license agreement with Oruka Therapeutics to apply Hypercon technology to ORKA-001, a treatment for psoriasis and related inflammatory diseases. The deal grants Oruka exclusive rights for IL-23p19 in psoriatic disease and an option for one additional target, with Halozyme receiving an upfront payment, milestones, and mid-single digit royalties. CEO Dr.
Key figures
- Drug Name
- ORKA-001
- Royalty rate
- mid-single digit
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.